Desensitization and resensitization of norepinephrine release in the rat hippocampus with repeated nicotine administration

doi:10.1016/S0304-3940(98)00018-4

Neuroscience Letters

Volume 241, Issues 2–3, 30 January 1998, Pages 147-150

https://doi.org/10.1016/S0304-3940(98)00018-4 Get rights and content

Abstract

Desensitization of norepinephrine release was investigated with repeated intravenous (i.v.) infusions of nicotine and in vivo microdialysis of the hippocampus. At 100 min intervals, rats received three infusions of one of the following doses of nicotine: 0.045, 0.09 or 0.135 mg/kg. Doses of 0.09 mg/kg or higher increased norepinephrine release (F=2.41, P<0.05). However, the norepinephrine response to the second or third infusion was significantly reduced, compared to the first. The extent of desensitization and rate of resensitization was investigated further by administering consecutive infusions of nicotine (0.135 mg/kg) 40, 60, 100 or 200 min apart. Less norepinephrine was released after a second nicotine infusion given 40 to 100 min later, but this was not reduced further by a third infusion. Norepinephrine release was unchanged with a 200 min inter-infusion interval. Therefore, in the hippocampus, maximal desensitization of nicotine-stimulated norepinephrine release occurs as early as 40 min and persists for at least 100 min; thereafter, resensitization becomes the dominant process.

Section snippets

Acknowledgements

Supported by NIDA DA03977 (to B.M.S).

References (28)

N.L. Benowitz
Cigarette smoking and nicotine addiction
Med. Clin. North. Am.
(1992)
M.P. Brazell et al.
Effect of acute administration of nicotine on in vivo release of noradrenaline in the hippocampus of freely moving rats: a dose-response and antagonist study
Neuropharmacology
(1991)
L. Dong et al.
Desensitization of central nicotinic cardiovascular effects by nicotine isomers and a quaternary analogue
Pharmacol. Biochem. Behav.
(1991)
G.H. Hall et al.
Effect of nicotine and other drugs on the release of ³H-noradrenaline from the hypothalamus
Biochem. Pharmacol.
(1972)
J.A. Kiritsy-Roy et al.
Tolerance to nicotine-induced sympathoadrenal stimulation and cross-tolerance to stress: differential central and peripheral mechanisms
Neuropharmacology
(1990)
M.J. Marks et al.
Influence of kinetics of nicotine administration on tolerance development and receptor levels
Pharmacol. Biochem. Behav.
(1987)
S.N. Mitchell
Role of the locus coeruleus in the noradrenergic response to a systemic administration of nicotine
Neuropharmacology
(1993)
Balfour, D.J.K. and Benwell, M.E.M., Desensitization of the stimulatory effects of nicotine on dopamine secretion in...
P. Boska et al.
Desensitization to nicotinic cholinergic agonists and K⁺, agents that stimulate catecholamine secretion, in isolated adrenal chromaffin cells
J. Neurochem.
(1984)
A.E. Bullock et al.
Nicotine tolerance in chromaffin cell cultures: acute and chronic exposure to smoking-related nicotine doses
J. Neurochem.
(1994)

M.I. Damaj et al.

Characterization and modulation of acute tolerance to nicotine in mice

J. Pharmacol. Exp. Ther.

(1996)

Y. Fu et al.

Adrenocorticotropin response and nicotine-induced norepinephrine secretion in the rat paraventricular nucleus are mediated through brainstem receptors

Endocrinology

(1997)

Lippiello, P.M., Bencherif, M and Prince, R.J., The role of desensitization in CNS receptor function. In P.B.S. Clarke,...

Marks, M.J., Grady, S.R., Robinson, S.F., Bullock, A.E. and Collins, A.C., Biochemical measures of nicotinic receptor...

Cited by (17)

Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning
2007, Pharmacology Biochemistry and Behavior
Bupropion, a norepinephrine and dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, facilitates smoking cessation and reduces some symptoms of nicotine withdrawal. However, the effects of bupropion on nicotine withdrawal-associated deficits in learning remain unclear. The present study investigated whether bupropion has effects on contextual and cued fear conditioning following withdrawal from chronic nicotine or when administered alone. Bupropion was administered alone for a range of doses (2.5, 5, 10, 20 or 40 mg/kg), and dose-dependent impairments in contextual and cued fear conditioning were observed (20 or 40 mg/kg). Follow-up studies investigated if bupropion disrupted acquisition or expression of fear conditioning. Bupropion (40 mg/kg) administration on training day only produced deficits in contextual fear conditioning. Alternatively, bupropion (20 or 40 mg/kg) administration during testing dose-dependently produced deficits in contextual and cued fear conditioning. To test the effect of bupropion on nicotine withdrawal, mice were withdrawn from 12 days of chronic nicotine (6.3 mg/kg/day) or saline treatment. Withdrawal from chronic nicotine disrupted contextual fear conditioning; however, 5 mg/kg bupropion reversed this deficit. Overall, these results indicate that a low dose of bupropion can reverse nicotine withdrawal deficits in contextual fear conditioning, but that high doses of bupropion produce deficits in fear conditioning.
Norepinephrine release in amygdala of rats during chronic nicotine self-administration: An in vivo microdialysis study
2003, Neuropharmacology
The essential role of the amygdala in learning and memory, including cue-associated learning, is influenced by local release of norepinephrine (NE). The current study investigated changes in amygdaloid NE secretion in rats learning to self-administer nicotine in an unlimited access model (23 h/day). In vivo microdialysis of NE was performed for 9 h intervals during three phases of nicotine self-administration: acquisition (day 1); early maintenance, when self-administration rates first stabilized (day 8.4±0.7); and later, during fully stable maintenance (day 17.6±1.0). On day 1, a greater number of self-administration episodes (SAEs) were associated with elevated NE levels in rats bar-pressing for nicotine (88% vs. 39% with saline). By early maintenance, such episodes increased threefold and overall NE levels were greater. During later maintenance, however, bar-pressing behavior was similar and NE was elevated by the first SAE of the day, but total daily NE levels were no longer elevated. In all the three phases, the enhanced NE release during the first daily SAE did not occur in the last SAE 9 h later. Thus, in an animal model of unlimited nicotine self-administration that approximates the human pattern of nicotine consumption via smoking, the amygdaloid NE response to nicotine diminishes over each day and with the stabilization of self-administration. The decline of amygdaloid NE secretion after long-term nicotine self-administration likely reflects desensitization to the pharmacological effects of nicotine. In addition, amygdaloid NE release, which enhances the consolidation of amygdala-dependent memory, may no longer be necessary once self-administration behavior has been established.
Local α-bungarotoxin-sensitive nicotinic receptors in the nucleus accumbens modulate nicotine-stimulated dopamine secretion in vivo
2000, Neuroscience
Nicotinic cholinergic receptors in the ventral tegmental area are required for the accumbal dopamine response to systemic nicotine. In contrast, the role of nicotinic receptors located within the nucleus accumbens itself has not been clarified for systemically administered nicotine. In the present study, in vivo microdialysis of accumbal dopamine secretion and receptor antagonist blockade in both the ventral striatal nucleus accumbens and the midbrain ventral tegmental area were used to evaluate this question. The nicotinic receptor antagonists methyllycaconitine or mecamylamine were delivered through the accumbal dialysis probe, followed by 0.09 mg/kg nicotine (i.v.). The α7 subunit antagonist methyllycaconitine inhibited 71% of the dopamine response (P<0.01), whereas mecamylamine was completely ineffective. In addition, the classical α7 subunit antagonist α-bungarotoxin infused into the nucleus accumbens adjacent to the microdialysis probe, significantly reduced dopamine release by 0.065 or 0.09 mg/kg nicotine (i.v.; P<0.05). Combined, these data indicate the involvement of α7 subunit-containing nicotinic receptors in the nucleus accumbens. In contrast, local infusion of mecamylamine into the ventral tegmental area effectively blocked nicotine-induced accumbal dopamine release. Simultaneous infusions of methyllycaconitine into the accumbens and mecamylamine into the ventral tegmental area induced greater blockade of nicotine-stimulated dopamine secretion than methyllycaconitine or mecamylamine alone.
In conclusion, the present study demonstrates that different types of nicotinic cholinergic receptors, located in the ventral striatal nucleus accumbens (α-bungarotoxin sensitive and mecamylamine insensitive) and the midbrain ventral tegmental area (mecamylamine sensitive), may be required for the full effects of nicotine on the mesostriatal dopaminergic pathway. While activation of nicotinic cholinergic receptors in the ventral tegmentum is required for the accumbal dopamine response to systemic nicotine, accumbal nicotinic receptors themselves act as modulators of this response. This fine tuning of the dopamine reward pathway through α7 nicotinic cholinergic receptors in the nucleus accumbens may amplify the secretion of dopamine, allowing a subthreshold brain concentration of nicotine to become an effective stimulus for dopamine secretion.
Nicotinic receptors modulating ACh release in rat cortical synaptosomes: Role of Ca<sup>2+</sup> ions in their function and desensitization
1999, Neurochemistry International
Cholinergic nerve terminals in the central nervous system are endowed with both muscarinic and nicotinic autoreceptors, mediating inhibition, and enhancement of acetylcholine release, respectively. Exogenous acetylcholine inhibited the K⁺(15 mM)-evoked overflow of [³H]acetylcholine from superfused rat neocortical synaptosomes; however, in the presence of atropine, this muscarinic inhibition was reversed into a nicotinic potentiation when acetylcholine was added concomitantly with high-K⁺, but not before depolarization. Increasing concentrations of acetylcholine (plus atropine), nicotine and (+)-anatoxin-a produced elevations of the K⁺-evoked [³H]acetylcholine overflow resulting in bell-shaped concentration-response curves. Synaptosomes pretreated with different concentrations (10 μM to 0.001 μM) of acetylcholine or nicotine responded to a subsequent nicotinic stimulus (10 μM acetylcholine plus 0.1 μM atropine, in 15 mM K⁺) in a manner reflecting varying degrees of desensitization. This desensitization could be reversed by washings with standard medium and desensitization was attenuated when external Ca²⁺ ([Ca²⁺]_e) was decreased. Lowering of [Ca²⁺]_e or chelation of internal Ca²⁺ with 1,2-bis(2-aminophenoxy)ethone-N,N,N′,N′-tetracetic acid acetoxymethylester (BAPTA-AM) permitted the nicotinic response to acetylcholine alone (no atropine added) to prevail over the muscarinic response. Pretreatment with BAPTA-AM could however not prevent desensitization by acetylcholine (10 or 0.001 μM). The data indicate that Ca²⁺ ions are involved in determining the balance between muscarinic and nicotinic autoreceptor function and in the desensitization of nicotinic autoreceptors.
Involvement of neuronal β<inf>2</inf> subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: Implications for pharmacotherapies
2014, Journal of Clinical Pharmacy and Therapeutics
Biological basis of tobacco addiction: Implications for smoking-cessation treatment
2010, Indian Journal of Psychiatry

View all citing articles on Scopus

View full text

Desensitization and resensitization of norepinephrine release in the rat hippocampus with repeated nicotine administration

Abstract

Section snippets

Acknowledgements

Med. Clin. North. Am.

Neuropharmacology

Pharmacol. Biochem. Behav.

Biochem. Pharmacol.

Neuropharmacology

Pharmacol. Biochem. Behav.

Neuropharmacology

Desensitization to nicotinic cholinergic agonists and K+, agents that stimulate catecholamine secretion, in isolated adrenal chromaffin cells

J. Neurochem.

Nicotine tolerance in chromaffin cell cultures: acute and chronic exposure to smoking-related nicotine doses

J. Neurochem.

Characterization and modulation of acute tolerance to nicotine in mice

J. Pharmacol. Exp. Ther.

Adrenocorticotropin response and nicotine-induced norepinephrine secretion in the rat paraventricular nucleus are mediated through brainstem receptors

Endocrinology

Desensitization to nicotinic cholinergic agonists and K⁺, agents that stimulate catecholamine secretion, in isolated adrenal chromaffin cells